Straits Times Index
3,367.90 +29.33 (+0.88%) S&P 500
5,464.53 -10.56 (-0.19%) Dow
39,129.34 -40.18 (-0.10%) Nasdaq
17,824.10 -55.20 (-0.31%) Bitcoin USD
62,856.50 -129.62 (-0.21%) CMC Crypto 200
1,344.63 +0.12 (+0.01%)
REGN Jul 2024 995.000 put
| Previous close | 2.3500 |
| Open | 1.5100 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 995.00 |
| Expiry date | 2024-07-19 |
| Day's range | 1.5100 - 2.3500 |
| Contract range | N/A |
| Volume | |
| Open interest | 168 |
Simply Wall St.Insiders At Regeneron Pharmaceuticals Sold US$26m In Stock, Alluding To Potential Weakness
The fact that multiple Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) insiders offloaded a considerable amount of...
ZacksRegeneron (REGN) Gets Positive CHMP Opinion for Lymphoma Drug
Regeneron (REGN) gets positive CHMP recommendation for odronextamab for the treatment of adults with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma.
BenzingaWhat's Going On With Regeneron Pharmaceuticals Stock On Friday?
On Friday, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion recommending conditional approval of odronextamab for relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy. Relapsed/refractory (R/R) follicular lymphoma (FL) refers to cases where FL comes back after initial treatment (relapsed) or
